A commentary on "An artificial intelligence model to predict survival and chemotherapy benefits for gastric cancer patients after gastrectomy development and validation in international multicenter cohorts".
作者信息
Liu Zhi-Peng, Dai Hai-Su, Zhang Yan-Qi, Yin Xian-Yu, Chen Zhi-Yu
机构信息
Department of Hepatobiliary Surgery, Southwest Hospital, Third Military Medical University (Amy Medical University).
Department of Health Statistics, College of Military Preventive Medicine, Third Military Medical University (Army Medical University), Chongqing, China.
出版信息
Int J Surg. 2023 Jan 1;109(1):1-2. doi: 10.1097/JS9.0000000000000078.
Abstract
摘要
相似文献
1
A commentary on "An artificial intelligence model to predict survival and chemotherapy benefits for gastric cancer patients after gastrectomy development and validation in international multicenter cohorts".对《一种用于预测胃癌患者胃切除术后生存及化疗获益的人工智能模型：在国际多中心队列中的开发与验证》的述评
Int J Surg. 2023 Jan 1;109(1):1-2. doi: 10.1097/JS9.0000000000000078.
2
An artificial intelligence model to predict survival and chemotherapy benefits for gastric cancer patients after gastrectomy development and validation in international multicenter cohorts.开发并验证国际多中心队列中用于预测胃癌患者胃切除术后生存和化疗获益的人工智能模型。
Int J Surg. 2022 Sep;105:106889. doi: 10.1016/j.ijsu.2022.106889. Epub 2022 Sep 6.
3
A new scoring system to evaluate adjuvant chemotherapy for patients with T2N0M0 gastric cancer after D2 gastrectomy.一种新的评分系统，用于评估 D2 胃切除术后 T2N0M0 期胃癌患者的辅助化疗。
World J Gastroenterol. 2022 Oct 14;28(38):5626-5635. doi: 10.3748/wjg.v28.i38.5626.
4
Predictive test for chemotherapy response in resectable gastric cancer: a multi-cohort, retrospective analysis.可切除胃癌化疗反应的预测性检测：多队列、回顾性分析。
Lancet Oncol. 2018 May;19(5):629-638. doi: 10.1016/S1470-2045(18)30108-6. Epub 2018 Mar 19.
5
Adjuvant albumin-bound paclitaxel combined with S-1 vs. oxaliplatin combined with capecitabine after D2 gastrectomy in patients with stage III gastric adenocarcinoma: a phase III multicenter, open-label, randomized controlled clinical trial protocol.白蛋白结合型紫杉醇辅助治疗联合 S-1 对比奥沙利铂联合卡培他滨用于 D2 胃切除术后 III 期胃腺癌患者的 III 期多中心、开放标签、随机对照临床试验方案。
BMC Cancer. 2021 Jan 12;21(1):56. doi: 10.1186/s12885-020-07772-7.
6
Impact of postoperative infectious complications on adjuvant chemotherapy administration after gastrectomy for advanced gastric cancer.术后感染性并发症对进展期胃癌根治术后辅助化疗的影响。
Jpn J Clin Oncol. 2021 Mar 3;51(3):379-386. doi: 10.1093/jjco/hyaa223.
7
Adjuvant chemotherapy for elderly patients (aged 70 or older) with gastric cancer after a gastrectomy with D2 dissection: A single center experience in Korea.D2 根治性胃切除术后老年（70 岁及以上）胃癌患者的辅助化疗：韩国单中心经验
Asia Pac J Clin Oncol. 2015 Dec;11(4):282-7. doi: 10.1111/ajco.12349. Epub 2015 Apr 9.
8
Adjuvant chemotherapy may be unnecessary for ypT0-2N0 gastric cancer patients after neoadjuvant chemotherapy and curative gastrectomy.对于接受新辅助化疗及根治性胃切除术后的ypT0-2N0期胃癌患者，辅助化疗可能并无必要。
Chin Med J (Engl). 2023 Aug 20;136(16):2002-2004. doi: 10.1097/CM9.0000000000002682. Epub 2023 Jun 26.
9
[Safety and efficacy of adjuvant chemotherapy with oxaliplatin and S-1 for patients with locally advanced gastric cancer after D2 lymph nodes dissection].奥沙利铂联合S-1辅助化疗用于D2淋巴结清扫术后局部进展期胃癌患者的安全性和疗效
Zhonghua Wei Chang Wai Ke Za Zhi. 2021 Feb 25;24(2):145-152. doi: 10.3760/cma.j.cn.441530-20201016-00561.
10
Risk Factors for Poor Compliance with Adjuvant S-1 Chemotherapy for Gastric Cancer: A Multicenter Retrospective Study.胃癌辅助 S-1 化疗依从性差的危险因素：一项多中心回顾性研究。
Ann Surg Oncol. 2017 Sep;24(9):2639-2645. doi: 10.1245/s10434-017-5923-2. Epub 2017 Jun 12.
Zotero 插件